SAN CARLOS, Calif.--(BUSINESS WIRE)--Glycomine, Inc., a biotechnology company focused on developing new therapies for orphan diseases, announced today that the U.S. Food and Drug Administration (FDA) ...
SAN CARLOS, Calif., April 02, 2026--(BUSINESS WIRE)--Glycomine, Inc. announced today that enrollment has been completed in the Phase 2b POLAR study, a global, randomized, double-blind, ...
SAN CARLOS, Calif.--(BUSINESS WIRE)--Glycomine, Inc., a clinical-stage biotechnology company focused on developing new therapies for orphan diseases, announced the first pediatric patient has been ...
SAN CARLOS, Calif., September 03, 2025--(BUSINESS WIRE)--Glycomine, Inc. announced today that the first participant has been dosed in the global Phase 2b study, called POLAR. This randomized ...
This study in 139 patients with PMM2-CDG represents the largest prospective natural history dataset with more than 300 patient-years of data collected to date Data from this study lay the groundwork ...
NEW YORK, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated ...
Greenwood Genetic Center (GGC) researchers are reporting the discovery of a mechanism that contributes to the tissue phenotypes seen in PMM2-CDG, the most common of the congenital disorders of ...
Greenwood Genetic Center (GGC) researchers are reporting the discovery of a mechanism that contributes to the tissue phenotypes seen in PMM2-CDG, the most common of the congenital disorders of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results